Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study
This extensive study in China demonstrated that RC48 has excellent therapeutic potential for both HER2-positive and HER2-low MBC with a favorable safety profile. The study also suggests that combination therapy significantly boosts efficacy beyond monotherapy, indicating a promising avenue for future ADC development.
Authors
- Min Zha (ORCID: https://orcid.org/0000-0002-0499-9224)
- Xinyu Wu (ORCID: https://orcid.org/0000-0002-1117-5098)
- Rongrong Lu
- Fei Qu
- Xiang Huang (ORCID: https://orcid.org/0000-0003-0180-103X)
- Zhengxiang Han (ORCID: https://orcid.org/0000-0003-2463-8933)
- H. Li (ORCID: https://orcid.org/0000-0003-2407-8948)
- Yongmei Yin (ORCID: https://orcid.org/0000-0003-3335-369X)
- Dongyan Cai
- Wěi Li (ORCID: https://orcid.org/0000-0002-9522-4474)
- Qian Liu (ORCID: https://orcid.org/0000-0001-9832-596X)
- Yuan Yuan (ORCID: https://orcid.org/0000-0002-7394-9036)
Institutions
- Xuzhou Medical College (CN)
- Shandong Tumor Hospital (CN)
- Wuxi Fourth People's Hospital (CN)
- Jiangsu Cancer Hospital (CN)
- Jiangsu Province Hospital (CN)
- Shandong First Medical University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-11-08
- DOI
- https://doi.org/10.3389/fonc.2024.1435485
- Citations
- 5
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- National Natural Science Foundation of China
- Chinese Society of Clinical Oncology